Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective

. 2021 Dec ; 11 (6) : 2123-2131. [epub] 20211112

Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium print-electronic

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid34767181
Odkazy

PubMed 34767181
PubMed Central PMC8611144
DOI 10.1007/s13555-021-00621-w
PII: 10.1007/s13555-021-00621-w
Knihovny.cz E-zdroje

INTRODUCTION: Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2-5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). METHODS: The objective of this study was to evaluate the efficacy of dupilumab for the treatment of AD from the patients' perspective using patient-reported outcome data from four clinical trials (CHRONOS, SOLO 1&2, and CAFÉ) in patients (N = 1553) receiving either the approved 300 mg q2w dupilumab with/without topical corticosteroids (TCS) dose or control (placebo or placebo + TCS). Patient Global Assessment of Disease Status (PGADS) was used to measure patients' well-being and Patient Global Assessment of Treatment Effect (PGATE) was used to measure treatment efficacy. Patients were asked "Considering all the ways in which your eczema affects you, indicate how well you are doing" to assess their perception of well-being and "How would you rate the way your eczema responded to the study medication?" to assess their perception of treatment effect. Possible responses for both metrics included poor, fair, good, very good, and excellent. RESULTS: In all four studies, a significantly higher proportion of dupilumab-treated patients reported "Good"/"Very Good"/"Excellent" disease status from week 2 through study end versus control (CHRONOS, 52 weeks: 69.8% vs. 25.1%; SOLO 1&2, 16 weeks: 59.5% vs. 24.6%; CAFÉ, 16 weeks: 84.1% vs. 45.4%; all P < 0.0001), and significantly more dupilumab-treated patients reported "Good"/"Very Good"/"Excellent" treatment efficacy versus control (CHRONOS: 72.6% vs. 24.8%; SOLO 1&2: 65.0% vs. 21.1%; CAFÉ, 16 weeks: 85.0% vs. 36.1%; all P < 0.0001). CONCLUSION: Adult patients with AD perceived that dupilumab with/without concomitant TCS was highly efficacious and improved overall disease status and well-being as early as week 2 and throughout treatment periods up to 1 year. Video Abstract (MP4 90521 kb).

Zobrazit více v PubMed

Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110. PubMed PMC

Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293. doi: 10.1111/all.13401. PubMed DOI

Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498. doi: 10.1016/j.jaad.2015.10.043. PubMed DOI

Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Investig Dermatol. 2015;135(1):56–66. doi: 10.1038/jid.2014.325. PubMed DOI

Sibbald C, Drucker AM. Patient burden of atopic dermatitis. Dermatol Clin. 2017;35(3):303–316. doi: 10.1016/j.det.2017.02.004. PubMed DOI

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: 10.1038/nrd4624. PubMed DOI

Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768. PubMed DOI

Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8. PubMed DOI

Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020. PubMed DOI

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1. PubMed DOI

Simpson EL. Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb) 2017;7(2):243–248. doi: 10.1007/s13555-017-0181-6. PubMed DOI PMC

Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD) J Am Acad Dermatol. 2016;75(3):506–515. doi: 10.1016/j.jaad.2016.04.054. PubMed DOI

de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156. PubMed DOI

Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi: 10.1016/j.jaad.2019.07.074. PubMed DOI

Thaci D, Simpson EL, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) J Dermatol Sci. 2019;94(2):266–275. doi: 10.1016/j.jdermsci.2019.02.002. PubMed DOI

DUPIXENT® (dupilumab) injection, for subcutaneous use [prescribing information]. Regeneron Pharmaceuticals, Inc, Tarrytown, NY2020. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf. Accessed 1 Feb 2021.

European Medicines Agency. Dupixent (dupilumab). Accessed 1 Feb 2021; https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent#authorisation-details-section. Accessed 1 Feb 2021.

EMA. European Medicines Agency: DUPIXENT® (dupilumab). Summary of product characteristics. 2021. https://ec.europa.eu/health/documents/community-register/2019/20190801145601/anx_145601_en.pdf. Accessed Mar 2021.

Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Dermato Venereol. 2021;101(2):00402. doi: 10.2340/00015555-3751. PubMed DOI PMC

Wei W, Anderson P, Gadkari A, et al. Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey. Am J Clin Dermatol. 2017;18(6):825–835. doi: 10.1007/s40257-017-0284-y. PubMed DOI PMC

Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatol Treat. 2020;31(6):606–614. doi: 10.1080/09546634.2019.1612836. PubMed DOI

Spekhorst LS, Ariëns LFM, Schaft J, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. Allergy. 2020;75(9):2376–2379. doi: 10.1111/all.14324. PubMed DOI PMC

Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40–45. doi: 10.1016/j.anai.2020.07.026. PubMed DOI

Ariens LF, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000–1009. doi: 10.1016/j.jaad.2020.08.127. PubMed DOI

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147. doi: 10.1016/j.jaad.2020.08.051. PubMed DOI

Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464. doi: 10.7326/M15-0288. PubMed DOI

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...